Which startups have raised the most funding in the longevity market?
Download our beautiful pitch about the longevity market

In our longevity market deck, you will find everything you need to understand the market
The longevity market now spans cellular rejuvenation, aging therapeutics, preventive diagnostics, wearables, biological-age testing, nutrition, and other technologies designed to extend healthy human lifespan.
To make this fast-moving market easier to follow, we maintain a ranking of the leading longevity startups based on the cumulative amount of funding each company has raised.
We update this list every month as new longevity funding rounds are announced, companies raise additional capital, and better historical fundraising information becomes available.
And if you want to better understand this new industry, you can download our pitch covering the longevity market.
A quick summary table
| Metric | Value |
|---|---|
| Most funded startup | Altos Labs, $3.0B |
| Second most funded startup | Oura, $1.7B |
| Largest funding round | Altos Labs, $3.0B initial financing |
| Median funding | $31M |
| Share of funding captured by the top 10 | Approximately 67% |
| Median time since last round | Approximately 23 months |
| Startups that raised funding in the last 12 months | 29 confirmed |
| Longevity startups with at least $100M raised | 23 |
| Longevity funding captured by the top 3 | Approximately 40% |
| Active longevity startups in the ranking | 82 of 93 |

This chart, featured in our longevity market deck, illustrates yearly VC funding for longevity startups
Top startups in the longevity market ranked by total funding raised
Here is an updated table that ranks the top startups in the longevity market based on the total amount of funding they have raised to date.
The table also includes the total number of funding rounds, the date and size of the latest round, the financing type (e.g. Series A, equity financing), key investors, the startup’s current status (active, IPO, acquired, or shut down), and a confidence score based on the data collected (we excluded startups with very low data confidence, to make sure everything is reliable).
If you're interested in knowing how much these startups are worth, you can check our list of the top startups in the longevity market ranked by valuation.
| # | Startup | What They Do | Total Raised ($) | Total Rounds | Last Round Date | Last Round Amount ($) | Last Round Type | Key Investors | Current Stage | Confidence |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Altos Labs | Cellular rejuvenation therapeutics research | $3.0B | 1 | January 2022 | $3.0B | Initial Financing / Series A | ARCH Venture Partners, Jeff Bezos, Yuri Milner | Active | Strong |
| 2 | Oura | Smart ring health monitoring | $1.7B | 6 | October 2025 | $900M | Series E | Fidelity, Iconiq, Atreides | Active | Full |
| 3 | Neko Health | Preventive full-body health scanning | $1.0B | 3 | July 2026 | $700M | Series C | Lightspeed Venture Partners, O.G. Venture Partners, Atomico | Active | Full |
| 4 | BioSplice Therapeutics | Alternative-splicing therapies degenerative diseases | $770M | 7 | April 2021 | $120M | Series B / Equity | Eventide, aMoon, Sands Capital | Active | Partial |
| 5 | NewLimit | Epigenetic reprogramming longevity medicines | $710M | 4 | June 2026 | $435M | Series C | Founders Fund, Thrive Capital, Greenoaks | Active | Full |
| 6 | Insilico Medicine | AI drug discovery for aging | $524M | 8 | March 2025 | $110M | Series E | Value Partners Group, Warburg Pincus, Prosperity7 Ventures | IPO | Full |
| 7 | BioAge Labs | Aging biology therapeutics | $516M | 6 | September 2024 | $198M | IPO | Public investors, Sofinnova | IPO | Full |
| 8 | Calico Life Sciences | Aging biology and therapeutics research | $480M | 2 | 2018 (month undisclosed) | $240M | Corporate Equity | Alphabet | Active | Strong |
| 9 | Celularity | Placental cellular and regenerative therapies | $456M | 10 | 2025 (month undisclosed) | $5M | Equity / preferred-stock financings | Dragasac, Sorrento Therapeutics, Palantir | IPO | Partial |
| 10 | Human Longevity | Precision health and longevity diagnostics | $370M | 4 | August 2024 | $40M | Series B | TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners | Active | Strong |
| 11 | Function Health | Preventive diagnostics and health intelligence | $350M | 5 | November 2025 | $298M | Series B | Redpoint Ventures, a16z, Battery Ventures | Active | Partial |
| 12 | Unity Biotechnology | Therapies targeting diseases of aging | $345M | 8 | November 2023 | $4M | Post-IPO Equity | Existing warrant holders | Shutdown | Strong |
| 13 | Alzheon | Oral therapies for Alzheimer’s disease | $317M | 7 | February 2025 | $126M | Series E Extension | Alerce Medical Technology Partners | Active | Partial |
| 14 | Life Biosciences | Cellular rejuvenation therapies for aging | $266M | 6 | April 2026 | $80M | Series D | Undisclosed investors | Active | Strong |
| 15 | Juvenescence | Longevity therapeutics and drug discovery | $238M | 4 | May 2025 | $76M | Series B-1 | M42 | Active | Strong |
| 16 | Nura Bio | Neuroprotective aging medicines | $215M | 3 | June 2026 | $74M | Series B | The Column Group, Euclidean Capital, Sanofi Ventures | Active | Full |
| 17 | Viome Life Sciences | Microbiome-driven personalized preventive health | $200M | 5 | September 2024 | $25M | Series D | Khosla Ventures, Bold Capital, Marc Benioff | Active | Partial |
| 18 | Retro Biosciences | Cellular rejuvenation therapies | $180M | 3 | May 2026 | Undisclosed | Series A Extension | 4P Capital, Sam Altman | Active | Strong |
| 19 | SciNeuro Pharmaceuticals | Neurodegenerative disease drug development | $153M | 2 | December 2025 | $53M | Series B / Equity | Lilly Asia Ventures, ARCH Venture Partners | Active | Full |
| 20 | Aeovian Pharmaceuticals | Selective mTORC1 inhibitor therapeutics | $142M | 3 | December 2025 | $55M | Series B | Luma Group, CTI Life Sciences Fund, Foresite Capital | Active | Strong |
| 21 | Corsera Health | Preventive cardiovascular RNAi and AI | $130M | 2 | January 2026 | $80M | Series A | Forbion, Population Health Partners, John Maraganore | Active | Partial |
| 22 | Nuritas | AI-discovered bioactive peptide ingredients | $112M | 5 | December 2024 | $42M | Series C | M&G Investments, McWin Capital Partners, Grosvenor Food & AgTech | Active | Partial |
| 23 | Cambrian Bio | Longevity biotech therapeutics | $100M | 2 | 2022 (month undisclosed) | $80M | Series A | Apollo Health Ventures, KdT Ventures | Active | Partial |
| 24 | Fountain Life | Preventive longevity diagnostics and clinics | $98M | 2 | August 2025 | $18M | Series B | EOS Ventures, B.K. Modi, Todd Wanek | Active | Partial |
| 25 | Loyal | Dog longevity therapeutics | $89M | 4 | November 2024 | $45M | Series B | Bain Capital Ventures, First Round Capital | Active | Strong |
| 26 | L-Nutra | Longevity and medical nutrition programs | $87M | 3 | January 2026 | $37M | Series D Extension | Mubadala, Brentwood Associates, Stéphane Bancel | Active | Partial |
| 27 | Rejuveron Life Sciences / Centenara | Develops healthy-aging therapeutics portfolio | $76M | 2 | September 2023 | $75M | Series B + Convertible | Catalio Capital Management, Apeiron Investment Group, Mubadala Capital | Active | Partial |
| 28 | Timeline | Mitopure-based cellular longevity products | $75M | 3 | January 2024 | $66M | Series D | BOLD / L'Oréal, Nestlé Health Science | Active | Partial |
| 29 | CohBar | Mitochondrial-derived peptide therapeutics | $70M | 7 | October 2021 | $15M | Public Offering | Public-market investors | Acquired | Strong |
| 30 | Liom | Non-invasive glucose monitoring wearable | $67M | 4 | December 2025 | $16M | Series A Extension | Red Bull Ventures, Marc Maurer, Melih Odemis | Active | Partial |
| 31 | resTORbio | mTOR drugs for aging diseases | $65M | 2 | November 2017 | $40M | Series B | OrbiMed, Fidelity, Rock Springs Capital | Acquired | Full |
| 32 | Illimis Therapeutics | Neurodegenerative and immune disease therapeutics | $64M | 3 | July 2025 | $42M | Series B | DSC Investment, Aju IB, IMM Investment | Active | Partial |
| 33 | Neurable | Consumer brain-computer interface technology | $63M | 8 | December 2025 | $35M | Series A | Spectrum Moonshot Fund, Ascendo Venture Capital | Active | Partial |
| 34 | Elevian | Regenerative medicines for stroke recovery | $60M | 3 | September 2021 | $40M | Series A | Prime Movers Lab, BOLD Capital, Leslie Ventures | Active | Strong |
| 35 | Blueprint | Consumer longevity health optimization platform | $60M | 2 | December 2025 | Undisclosed | Seed / Venture | North Island Ventures | Active | Partial |
| 36 | Gordian Biotechnology | In-vivo age-disease drug discovery | $60M | 4 | November 2021 | Undisclosed | Series A | Longevity Fund, Gigafund, Founders Fund | Active | Partial |
| 37 | Rubedo Life Sciences | Drugs targeting pathological senescent cells | $52M | 2 | April 2024 | $40M | Series A | Khosla Ventures, Ahren Innovation Capital, Hevolution Foundation | Active | Strong |
| 38 | Neuraly | Neurodegenerative disease drug development | $47M | 2 | July 2018 | $36M | Series A | D&D Pharmatech, Smilegate Investment, InterVest | Active | Strong |
| 39 | Arda Therapeutics | Targeted cell depletion therapies | $43M | 1 | October 2024 | $43M | Series A | Andreessen Horowitz, Two Sigma Ventures, GV | Active | Strong |
| 40 | Alkahest | Plasma-derived therapies for aging diseases | $41M | 2 | March 2015 | $38M | Corporate Equity | Grifols | Acquired | Full |
| 41 | Cellular Origins | Automated cell therapy manufacturing | $40M | 1 | December 2025 | $40M | Series A | Johnson & Johnson Innovation, Highland Europe, BGF | Active | Full |
| 42 | LyGenesis | Regrows organs using lymph nodes | $40M | 3 | October 2024 | $18M | Series A-IV | Undisclosed investors | Active | Partial |
| 43 | Tolerance Bio | Thymus-based immune tolerance therapies | $35M | 2 | June 2026 | $15M | Seed Extension / Early-stage | Beyond Celiac Investments, BioAdvance | Active | Strong |
| 44 | Jocasta Neuroscience | Klotho therapeutics for cognitive decline | $35M | 1 | August 2025 | $35M | Series A | True Ventures, Moore Strategic Ventures, SC8 Investments | Active | Full |
| 45 | Gero | AI discovers aging drug targets | $34M | 4 | June 2026 | $17M | Series B | Chugai Pharmaceutical, Melnichek Investments | Active | Strong |
| 46 | Amplifier Therapeutics | Develops AMPK activator therapeutics | $33M | 1 | October 2023 | $33M | Series A | RA Capital Management, Future Ventures, Cambrian Bio | Active | Full |
| 47 | MindImmune Therapeutics | Neuroinflammation therapies for brain diseases | $31M | 3 | November 2025 | $11M | Series A Extension | Dolby Family Ventures, Gates Frontier, Pfizer Ventures | Active | Strong |
| 48 | Rejuvenate Bio | Gene therapies for age-related diseases | $30M | 2 | June 2026 | $20M | Venture / Private Equity | VCapital, Merck Animal Health, Digitalis Ventures | Active | Partial |
| 49 | Turn Biotechnologies | Epigenetic cellular rejuvenation therapies | $29M | 4 | May 2024 | Undisclosed | Venture | Methuselah Fund | Active | Partial |
| 50 | Repair Biotechnologies | Reverses cholesterol-driven age-related disease | $27M | 8 | November 2025 | $5M | Venture Equity | Healthspan Capital, LongevityTech.Fund, Bioverge | Active | Strong |
| 51 | Elysium Health | Science-based longevity health products | $26M | 3 | December 2016 | $20M | Series B | General Catalyst, Breyer Capital, Morningside Ventures | Active | Partial |
| 52 | Cyclarity Therapeutics | Anti-aging cholesterol therapies | $24M | 4 | December 2024 | $6M | Series A Tranche | Ki Tua Fund, Bill Liao | Active | Strong |
| 53 | Oisín Biotechnologies | Genetic medicines targeting aging mechanisms | $22M | 5 | July 2024 | $15M | Series A | AbbVie Ventures | Active | Partial |
| 54 | Junevity | siRNA cellular reprogramming therapeutics | $20M | 2 | December 2025 | $10M | Seed Extension | Goldcrest Capital, Godfrey Capital | Active | Full |
| 55 | Shift Bioscience | AI cellular rejuvenation platform | $18M | 2 | October 2024 | $16M | Seed | BGF, F-Prime Capital, Kindred Capital | Active | Strong |
| 56 | Deciduous Therapeutics | Immune therapies targeting senescent cells | $17M | 2 | December 2022 | $10M | Seed | 8VC, CRV, Longevity investors | Active | Strong |
| 57 | Longevica | Longevity therapeutics and lifespan research | $16M | 2 | November 2021 | $3M | Venture Round | Xploration Capital, Alexander Chikunov | Active | Partial |
| 58 | Generation Lab | Biological age diagnostic platform | $15M | 2 | October 2025 | $11M | Seed | Accel, Samsung Next, Aoki Labs | Active | Strong |
| 59 | Cirrus Therapeutics | Ocular aging gene therapies | $15M | 2 | August 2026 | $4M | Seed Extension | Cedars Sinai IPC, ClavystBio, Polaris Partners | Active | Full |
| 60 | Modulo Bio | Neuroimmune drugs for neurodegeneration | $14M | 2 | December 2024 | $6M | Seed | Initialized Capital | Active | Strong |
| 61 | Edifice Health | Measures and manages chronic inflammation | $14M | 2 | April 2021 | $12M | Series A | Leaps by Bayer, Paladin Capital, Ahren | Active | Full |
| 62 | GlycanAge | Glycan-based biological age diagnostics | $13M | 3 | December 2025 | $9M | Series A | LAUNCHub Ventures, Guinness Ventures, BrightCap Ventures | Active | Partial |
| 63 | Radar Therapeutics | Programmable RNA-sensing precision medicines | $13M | 1 | May 2024 | $13M | Seed | NFX Bio, Eli Lilly, Biovision Ventures | Active | Strong |
| 64 | Morphoceuticals | Bioelectric tissue and organ regeneration | $13M | 3 | October 2024 | $4M | Seed | Ferocity Capital | Active | Partial |
| 65 | Amphix Bio | Peptide therapies for neurological diseases | $13M | 1 | December 2025 | $13M | Seed | Undisclosed investor syndicate | Active | Strong |
| 66 | Circulate Health | Therapeutic plasma exchange longevity clinics | $12M | 2 | December 2025 | Undisclosed | Strategic / Early VC | Scrum Ventures | Acquired | Strong |
| 67 | Acorn Biolabs | Banks cells for regenerative treatments | $12M | 3 | May 2024 | $8M | Series A | Merz Aesthetics, TELUS Global Ventures, MDE Investments | Active | Full |
| 68 | Epiterna | Drugs that slow biological aging | $11M | 1 | August 2023 | $11M | Seed / Early VC | Prima Materia | Active | Full |
| 69 | Rejuvenation Technologies | Telomere-extending mRNA longevity therapeutics | $11M | 2 | September 2023 | $11M | Seed | Khosla Ventures, Shanda Ventures, Asymmetry Ventures | Active | Strong |
| 70 | Minovia Therapeutics | Mitochondrial augmentation cell therapies | $10M | 2 | January 2025 | Undisclosed | Seed / Venture | 4T Ventures | Active | Partial |
| 71 | Tally Health | Consumer epigenetic biological-age testing | $10M | 1 | April 2023 | $10M | Seed | Forerunner Ventures, L Catterton, G9 Ventures | Acquired | Full |
| 72 | AgelessRx | Longevity telehealth and clinical research | $9M | 3 | March 2026 | $5M | Equity / Venture | Pareto Holdings, 1/0 Capital, Rankin Ventures | Active | Partial |
| 73 | clock.bio | Cellular rejuvenation platform | $9M | 2 | October 2024 | $5M | Seed | LocalGlobe, BlueYard Capital, Onsight Ventures | Active | Strong |
| 74 | SENISCA | RNA therapies reverse cellular senescence | $9M | 3 | March 2024 | $5M | Seed | Emerging Longevity Ventures, QantX, R42 Group | Active | Strong |
| 75 | Grey Matter Neurosciences | Neuroscience aging therapies | $8M | 1 | 2023 (month undisclosed) | $8M | Seed | Apollo Health Ventures, Northpond Ventures | Active | Partial |
| 76 | MitoRx Therapeutics | Mitochondrial longevity drugs | $7M | 1 | November 2025 | $7M | Pre-Series A | Oshen Holdings SA, Fink Family Office | Active | Strong |
| 77 | Biopeak | Personalized preventive longevity healthcare | $7M | 3 | January 2026 | $3M | Seed Extension | NKSquared | Active | Strong |
| 78 | Thymmune Therapeutics | Regenerative thymus cell therapies | $7M | 1 | March 2023 | $7M | Seed | Pillar VC, NYBC Ventures, John Maraganore | Acquired | Strong |
| 79 | Cyclana Bio | Tissue-based endometriosis drug discovery | $7M | 1 | October 2025 | $7M | Pre-Seed | NFX, Eka VC, Cocoa VC | Active | Full |
| 80 | NaNotics | Nanomedicines remove pathological blood targets | $6M | 2 | October 2023 | $3M | Series A | LifeSpan Vision Ventures, Lauder Partners | Active | Low |
| 81 | Vincere Biosciences | Mitophagy therapeutics for neurodegeneration | $6M | 3 | 2025 (month undisclosed) | Undisclosed | Series A / Corporate Minority | HanAll Biopharma, Daewoong Pharmaceutical, Beiersdorf | Active | Low |
| 82 | Vasa Therapeutics | Therapies targeting cardiovascular aging | $6M | 2 | January 2024 | $6M | Series Seed | Orphinic Scientific, NuFund Venture Group, SeedFolio | Active | Partial |
| 83 | Genflow Biosciences | Gene therapies for aging | $6M | 3 | 2024 (month undisclosed) | $1M | Equity Placing | Existing shareholders | Active | Strong |
| 84 | Biolytica | Personalized health-data longevity platform | $6M | 2 | May 2023 | $6M | Seed | Maximon | Active | Partial |
| 85 | Leucadia Therapeutics | Restores cerebrospinal-fluid drainage Alzheimer’s | $5M | 2 | July 2019 | Undisclosed | Seed | Methuselah Foundation, Methuselah Fund | Active | Low |
| 86 | Tomorrow Bio | Human cryopreservation services | $5M | 1 | 2022 (month undisclosed) | $5M | Seed | Apeiron Investment Group, Deep Knowledge Group | Active | Low |
| 87 | Everlab | Preventive longevity diagnostics | $4M | 1 | 2024 (month undisclosed) | $4M | Seed | Blackbird Ventures, Rampersand | Active | Low |
| 88 | NOVOS | Science-backed consumer longevity products | $4M | 2 | March 2026 | Undisclosed | Strategic VC | Unilever Ventures | Active | Partial |
| 89 | Mito Health | AI-powered personalized preventive healthcare | $4M | 2 | March 2025 | $2M | Seed | Y Combinator, Capital X, XA Network | Active | Strong |
| 90 | Bionic Health | AI-powered preventive longevity care | $3M | 2 | July 2024 | Undisclosed | Seed Extension | TowerView Ventures, Alumni Ventures, Triangle Tweener Fund | Acquired | Partial |
| 91 | Matter Bio | Aging biotechnology platform | $3M | 1 | 2024 (month undisclosed) | $3M | Seed | Longevity angels | Active | Low |
| 92 | ImmuneAGE Bio | Rejuvenates aging immune stem cells | $2M | 2 | July 2024 | $2M | Seed | 1517 Fund, Emerging Longevity Ventures, Healthspan Capital | Active | Partial |
| 93 | NADMED | NAD metabolism diagnostics | $2M | 1 | 2022 (month undisclosed) | $2M | Seed | Finnish health-tech investors | Active | Partial |

This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
Key funding trends in the longevity market
Insights
- Funding in the longevity market is highly concentrated. The ten largest companies have raised approximately $9.5B, around 67% of the roughly $14.2B represented across the 93 startups in this ranking.
- The typical longevity startup is much smaller than the market leaders suggest. Median cumulative funding is only $31M, while the average is roughly $152M because a small number of billion-dollar companies pull the mean sharply higher.
- Only 23 longevity startups have raised at least $100M, yet those companies account for approximately $12.3B, or almost 87% of all capital represented in the ranking.
- Recent fundraising remains active across the longevity market. At least 29 companies completed a documented funding round during the 12 months ending September 2026, including Neko Health, NewLimit, Nura Bio and Life Biosciences.
- Large later rounds can transform a longevity company’s capital base quickly. Oura's $900M Series E represents roughly 53% of lifetime funding, while Neko Health's $700M Series C represents about 70%.
- Capital concentration does not belong only to therapeutics. Oura and Neko Health have raised roughly $2.7B combined, showing how consumer monitoring and preventive diagnostics can compete with drug-development platforms for institutional capital.
- NewLimit and Life Biosciences illustrate very different funding paths within cellular rejuvenation. NewLimit reached $710M across four rounds, while Life Biosciences accumulated $266M across six rounds.
- Unity Biotechnology is an important reminder for longevity investors. Approximately $345M of cumulative funding still preceded shutdown, showing that substantial capitalization cannot remove clinical, biological, or development risk.

As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
A few word about our methodology
As you can see, we built a database that ranks startups in the longevity market based on their total cumulative fundraising. To create this ranking, we reviewed many sources and cross-checked information across multiple places.
Whenever possible, we prioritized official company communications, since they are the most reliable source for longevity funding amounts. When those were not available, we relied on reputable industry sources such as TechCrunch, Crunchbase, Financial Times or Forbes (to name a few).
We excluded random blogs, unverified websites, and any sources that could not be validated.
When longevity funding rounds were announced in other currencies such as euros, Swiss francs, Singapore dollars, Australian dollars, or rupees, we converted them into approximate USD equivalents for consistency.
Sometimes different sources report slightly different numbers, or the exact round size is not fully disclosed. In those cases, we flag the uncertainty and assign a confidence label to each longevity startup, visible in the last column.
Here is what they mean.
Full confidence: The company’s equity fundraising history can be reconstructed completely from public sources. The rounds, dates, amounts, and key investors are clearly identified, with no meaningful gaps.
Strong confidence: The fundraising history is largely complete and reliable. There may be a small missing detail, such as incomplete investor information or a minor round with limited data, but the overall record is clear.
Partial confidence: The main fundraising rounds can be identified, but the record is incomplete or somewhat mixed. Some rounds may be missing or certain funding events may be difficult to separate clearly.
Low confidence: Public information is too limited, inconsistent, or ambiguous to reliably reconstruct the company’s equity fundraising history.
When the confidence level is too low, we take a conservative approach and exclude the company from the ranking. We don’t want to include data that cannot be reliably verified.
This reflects how we conduct all our research, including the work behind our report covering the longevity market.
In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.
If you want the full detail on a specific calculation, feel free to contact us and we will gladly explain.
Finally, know that we update the dataset once per month, so come back here if you need fresh information.

This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Related blog posts
- What are the top startups in the longevity market?
- The most highly valued startups in the longevity market
- How strong is fundraising in the longevity market right now?
- All the recent funding deals in the longevity market
Who is the author of this content?
NEW MARKET PITCH TEAM
We track new markets so founders and investors can move fasterWe build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.
How we created this content 🔎📝
At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.
So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.
Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.